Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy

Abstract

Immunotherapy shows a lot of promise for addressing the problems with traditional cancer treatments. Researchers and clinicians are working to create innovative immunological techniques for cancer detection and treatment that are more selective and have lower toxicity. An emerging field in cancer therapy, immunomodulation offers patients an alternate approach to treating cancer. These therapies use the host’s natural defensive systems to identify and remove malignant cells in a targeted manner. Cancer treatment is now undergoing somewhat of a revolution due to recent developments in nanotechnology. Diverse nanomaterials (NMs) have been employed to overcome the limits of conventional anti-cancer treatments such as cytotoxic, surgery, radiation, and chemotherapy. Aside from that, NMs could interact with live cells and influence immune responses. In contrast, unexpected adverse effects such as necrosis, hypersensitivity, and inflammation might result from the immune system (IS)’s interaction with NMs. Therefore, to ensure the efficacy of immunomodulatory nanomaterials, it is essential to have a comprehensive understanding of the intricate interplay that exists between the IS and NMs. This review intends to present an overview of the current achievements, challenges, and improvements in using immunomodulatory nanomaterials (iNMs) for cancer therapy, with an emphasis on elucidating the mechanisms involved in the interaction between NMs and the immune system of the host.

Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications

“…These include scalability, reproducibility, prolonged regulatory approval processes, and patient heterogeneity. 283,284 Several clinical data indicate that developed nanomedicines may only be effective in certain subpopulations of patients. Therefore, effective clinical implemen- tation of these therapeutics depends on exploring strategies for patient stratification and treatment identification for trials.…”

Carbon Nanomaterials: Emerging Roles in Immuno-Oncology

“…Additionally, the size, shape, and chemical surface composition of several nanomaterials can determine the impact of their immunological regulation. This creates the unprecedented unpredictability of any new potential nanomedicine in any clinical trial [ 82 ]. This implies that there could be inconsistent results in clinical trials in cases where the size, shape, or surface compositions are slightly distorted.…”

The role of macrophages in rosacea: implications for targeted therapies

“…However, there are also several limitations and challenges associated with macrophage-targeted therapies ( 91 ). Targeting macrophages specifically while avoiding impact on other skin cell types is challenging due to the complex interactions among immune cells in the skin’s immune response ( 92 ). Additionally, the potential for the development of drug resistance and the risk of side effects, such as immunosuppression, must be carefully considered ( 93 ).…”